BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data from a Harvard-led team provide not only evidence of protective immunity following COVID-19 resolution, but also an antibody benchmark...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

In December, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) reported top-line data from 10 evaluable patients with platinum-sensitive or -resistant ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac plus twice-daily...
BioCentury | Jun 2, 2017
Clinical News

Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

...that the Dana-Farber Cancer Institute (Boston, Mass.) began a Phase Ib/II trial of the biotech’s DPX-E7...
...oropharyngeal, cervical and anal cancers. The open-label, U.S. trial will evaluate 2 priming doses of DPX-E7...
...tissue. Secondary endpoints include overall response rate (ORR), overall survival (OS) and progression-free survival (PFS). DPX-E7...
BioCentury | Apr 14, 2017
Clinical News

DPX-RSV: Additional Ph I data

Data from 7 healthy volunteers in a double-blind, placebo-controlled, Canadian Phase I trial showed that 25 µg intramuscular DPX-RSV led to an antigen-specific antibody response that was maintained at year 1 in 100% of patients....
BioCentury | Feb 9, 2017
Company News

Immunovaccine, Merck deal

Immunovaccine and Merck partnered to evaluate Immunovaccine’s DPX-Survivac in combination with Merck’s cancer drug Keytruda pembrolizumab plus low-dose cyclophosphamide in an open-label Phase II trial to treat advanced epithelial ovarian, fallopian tube or primary peritoneal...
BioCentury | Sep 5, 2016
Clinical News

DPX-Survivac: Additional Phase I/II data

Additional data from the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial in 54 evaluable patients with stage IIc-IV ovarian cancer showed that subcutaneous DPX-Survivac in combination with low-dose cyclophosphamide led...
BioCentury | Jul 25, 2016
Clinical News

DPX-RSV: Interim Phase I data

Interim data from a double-blind, placebo-controlled, Canadian Phase I trial in 40 healthy volunteers ages 50-64 showed that low- and high-dose intramuscular DPX-RSV led to antigen-specific antibody responses in 75% and 100% of patients, respectively....
BioCentury | Aug 24, 2015
Clinical News

DPX-RSV: Phase I started

Immunovaccine began the observer-blind, placebo-controlled, dose-escalation, Canadian Phase I trial to compare 2 dose levels of intramuscular DPX-RSV vs. the antigen contained in the vaccine plus an Alum adjuvant in about 40 healthy volunteers ages...
BioCentury | Aug 3, 2015
Company News

Immunovaccine, Incyte deal

The companies partnered non-exclusively to evaluate Immunovaccine’s DPX-Survivac in combination with epacadostat from Incyte plus low-dose oral cyclophosphamide in an open-label Phase Ib trial to treat platinum-sensitive ovarian cancer in about 20 patients who are...
Items per page:
1 - 10 of 37